Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Baxter Announces Divestiture of U.S. Generic Injectables Business to Hikma Pharmaceuticals

VIEWS: 11 PAGES: 2

DEERFIELD, Ill.--(EON: Enhanced Online News)--Baxter International Inc. (NYSE:BAX) announced today that it has entered into a definitive agreement to divest its U.S. generic injectables business to Hikma Pharmaceuticals PLC (LSE:HIK). The consideration for the divestiture arrangement totals approximately $112 million, subject to closing adjustments. The sale of this business will allow Baxter to redirect resources toward its proprietary, enhanced packaging offerings and formulation technologies, a style=

More Info
To top